Medicine
Gimoti 15 mg/0.07 mL nasal spray
Gimoti 15 mg/0.07 mL nasal spray is a prescription medicine containing Metoclopramide for nasal use, marketed by Evoke Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F) excursions permitted 15°C to 30°C (59°F…
Key facts
- Active ingredient (INN)
- Metoclopramide
- Brand
- Gimoti
- Strength
- 15 mg/0.07 mL
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 1 bottle
- Marketing authorisation holder
- Evoke Pharma
- Manufacturer
- Evoke Pharma
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F) excursions permitted 15°C to 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A03FA01 Metoclopramide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 June 2020
- Identifiers
- RxCUI 2380564, 2380570DailyMed set ID 95269b1f-779c-4ca0-9f86-e74e677f9900NDC 72089-307Application NDA209388
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, pump in 1 carton / 9.8 mL in 1 bottle, pump | 72089-307-15 | Evoke Pharma | 19 June 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 7 February 1979 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Metoclopramide
Clinical summary
Metoclopramide is a dopamine-2 receptor antagonist indicated for the treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy, among other approved uses. MedsAcross supplies Metoclopramide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MetoclopramideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Metoclopramide prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Gimoti 15 mg/0.07 mL nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.